©
Ypsomed
Addenbrooke’s Hospital and the Royal Papworth Hospital in Cambridge have started recruiting adults with cystic fibrosis-related diabetes to the CL4P-CF trial. The trial is investigating whether an automated insulin delivery system –CamAPS® FX – improves glucose control (as measured by glucose ‘time in range’) compared with standard insulin therapy plus a glucose sensor. This system is known by some as a ‘hybrid closed-loop system’ or an ‘artificial pancreas’.
Other study sites opening soon include Wythenshawe Hospital in Manchester, Oxford University Hospitals and the Royal Brompton Hospital in London.
We would like to thank the study participants and the Cystic Fibrosis Trust for their support; the trial is funded by the National Institute for Health and Care Research.
Read more about this trial for people living with cystic fibrosis-related diabetes.